4.6 Article

Schizophrenia-Time to Commit to Policy Change

Journal

SCHIZOPHRENIA BULLETIN
Volume 40, Issue -, Pages S165-S194

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/schbul/sbu006

Keywords

schizophrenia; health policy; quality of life; antipsychotics; psychotherapy; recovery

Categories

Funding

  1. F. Hoffmann-La Roche
  2. Janssen
  3. Otsuka
  4. Pfizer
  5. Reckitt Benckiser
  6. Abbott
  7. Amgen
  8. AstraZeneca
  9. Bristol-Myers Squibb
  10. Caja Navarra
  11. Centro de Investigacion Biomdica en Red de Salud Mental
  12. Fundacion Alicia Koplowitz
  13. Instituto de Salud Carlos III
  14. Janssen-Cilag
  15. Lundbeck
  16. Merck
  17. Ministerio de Ciencia e Innovacion
  18. Ministerio de Economia y Competitividad
  19. Ministerio de Sanidad
  20. Mutua Madrilena
  21. Oxford PharmaGenesis Ltd
  22. Roche
  23. Schering-Plough
  24. Servier
  25. Shire
  26. Takeda
  27. Department of Health for England
  28. Lilly

Ask authors/readers for more resources

Care and outcomes for people with schizophrenia have improved in recent years, but further progress is needed to help more individuals achieve an independent and fulfilled life. This report sets out the current need, informs policy makers and all relevant stakeholders who influence care quality, and supports their commitment to creating a better future. The authors recommend the following policy actions, based on research evidence, stakeholder consultation, and examples of best practice worldwide. (1) Provide an evidence-based, integrated care package for people with schizophrenia that addresses their mental and physical health needs. (2) Provide support for people with schizophrenia to enter and to remain in their community, and develop mechanisms to help guide them through the complex benefit and employment systems. (3) Provide concrete support, information, and educational programs to families and carers on how to enhance care for an individual living with schizophrenia in a manner that entails minimal disruption to their lives. (4) All stakeholders, including organizations that support people living with schizophrenia, should be consulted to regularly revise, update, and improve policy on the management of schizophrenia. (5) Provide support, which is proportionate to the impact of the disease, for research and development of new treatments. (6) Establish adequately funded, ongoing, and regular awareness-raising campaigns that form an integral part of routine plans of action. Implementation of the above recommendations will require engagement by every stakeholder, but with commitment from all, change can be achieved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available